Expand your clinical trials to China.
Through our partnership with Adicon Labs, we can support local testing
in China for the development of new therapies. Adicon has an integrated network of laboratories and is one of the top 3 independent clinical laboratories (ICL) in China.
With this relationship, biopharma companies can expand patient screening and accelerate recruitment for their clinical programs to China, while leveraging Guardant’s global footprint and commercialization expertise.
Guardant360 CDx has MLHW approval and is reimbursed
under the National Health Insurance system in Japan.
Guardant360 CDx has a growing CDx pipeline in Japan, with plans for in-country testing availability at the CAP-accredited Japan iPark Lab.
Partnering with world-renowned cancer centers in Europe,
enabling access to Guardant360.
Our partnership model provides access to in-country testing and is helping to accelerate testing adoption and reimbursement in these key regions.
Our first 2 partnerships are with Vall d’Hebron Institute of Oncology (VHIO)
in Spain and the Royal Marsden NHS Foundation Trust in the UK.
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma